Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial
Open accessAbstract
Background Type 1 diabetes remains an important health-care problem, with no disease-modifying therapies available in people with recent-onset, clinical type 1 diabetes. Adaptive trial designs, allowing faster evaluation of treatment modalities, remain underexplored in this stage of the disease. We aimed to identify the minimum effective dose of antithymocyte globulin (ATG) in people aged 5-25 years with recent-onset, clinical type 1 diabetes. Methods MELD-ATG was a phase 2, double-blind, randomised, placebo-controlled, multi-arm, adaptive dose-ranging, parallel-cohort trial done in 14 accredited trial centres in eight countries (the UK, Denmark, Germany, Finland, Italy, Belgium, Austria, and Slovenia). Participants aged 5-25 years, diagnosed with clinical, stage 3 type 1 diabetes 3-9 weeks before treatment, with random C-peptide concentrations 0·2 nmol/L or more and at least one diabetes-related autoantibody (GADA, IA-2A, or ZnT8) were randomly assigned by a web-based randomisation system into seven consecutive cohorts receiving placebo, 2·5 mg/kg ATG, 1·5 mg/kg ATG, 0·5 mg/kg ATG, or 0·1 mg/kg ATG. Participants in cohort 1 were randomly assigned 1:1:1:1:1, participants in cohorts 2 and 3 were randomly assigned 1:1:1:1, and participants in cohorts 4-7 were randomly assigned 1:1:1. All cohorts included one placebo group and one 2·5 mg/kg ATG group. The other groups were assigned to ATG doses that were determined based on accruing data and the decision of the dose determining committee. The trial cohorts were stratified by age group (5-9 years, 10-17 years, and 18-25 years) with block sizes varying by cohort. Concealment lists, outlining the treatment allocation, were only available for the pharmacists; participants and study teams were masked to treatment allocation. ATG was administered by an intravenous infusion over 2 consecutive days. The primary outcome was the area under the curve (AUC) of the stimulated C-peptide concentration during a 2-h mixed-meal tolerance test at 12 months measured as ln(AUC C-peptide + 1). Conditional on finding a statistically significant difference at p<0·05 for 2·5 mg/kg ATG versus placebo, the minimum effective dose of ATG was determined. All randomly assigned participants were included in the primary analysis. All participants who received the study drug were included in the safety analysis. The trial was registered at ClinicalTrials.gov (NCT04509791) and is completed. Findings Between Nov 24, 2020, and Dec 13, 2023, 152 people were recruited and screened, 117 of whom were randomly assigned (placebo n=31, 0·1 mg/kg ATG n=6, 0·5 mg/kg ATG n=35, 1·5 mg/kg ATG n=12, and 2·5 mg/kg n=33). 54 (46%) of 117 participants were male and 63 (54%) were female. Participants were mainly European. The 0·1 mg/kg dose and the 1·5 mg/kg dose were progressively dropped from the study. At 12 months, the mean ln(AUC C-peptide + 1) was 0·411 nmol/L per min (SD 0·032) in the placebo group and 0·535 nmol/L per min (0·032) in the 2·5 mg/kg ATG group. The mean difference in the ln(AUC C-peptide + 1) between 2·5 mg/kg ATG and placebo was 0·124 nmol/L per min (95% CI 0·043-0·205; p=0·0028). At 12 months, the mean ln(AUC C-peptide + 1) in the 0·5 mg/kg ATG group, the remaining middle dose, was 0·513 nmol/L per min (SD 0·032), with a mean baseline-adjusted difference from placebo of 0·102 nmol/L per min (95% CI 0·021-0·183; p=0·014). Cytokine release syndrome occurred in 11 (33%) of 33 participants in the 2·5 mg/kg ATG group, eight (24%) of 34 in the 0·5mg/kg ATG group, and no participants in the placebo group. Serum sickness occurred in 27 (82%) participants in the 2·5 mg/kg ATG group, 11 (32%) in the 0·5 mg/kg ATG group, and no participants in the placebo group. There were no deaths related to adverse events. Interpretation In young people with recent-onset, clinical type 1 diabetes, 2·5 mg/kg and 0·5 mg/kg ATG reduced loss of β-cell function, showing the potential of an affordable, repurposed agent, ATG, in a low and safe dose, as a disease-modifying agent in this population. Funding The European Union's Innovative Medicines Initiative 2 Joint Undertaking INNODIA.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A very recent trial assessing the efficacy and safety of low-dose ATG showed that β-cell function can be preserved with doses lower than previously considered effective and that the therapy is safe in children 5 years or older.
“A very recent trial assessing the efficacy and safety of lowdose ATG showed that βcell function can be preserved with doses lower than previously considered effective and that the therapy is safe in children 5 years or older.22”
From The future of type 1 diabetes therapy (2025) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,673 · see citing works
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829 · see citing works
Self-citationMechanisms of action of antithymocyte globulin: T-cell depletion and beyond
Mohty, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404683 · Cited by 613 · see citing works
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612 · see citing works
Adaptive Designs for Clinical Trials
Bhatt, D. L., & Mehta, C. R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510061 · Cited by 506 · see citing works
Battaglia, M., Ahmed, S., Anderson, M. S., Atkinson, M. A., Becker, D., Bingley, P. J., Bosi, E., Brusko, T. M., DiMeglio, L. A., Evans-Molina, C., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0880 · Cited by 351 · see citing works
Self-citationKeymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., de Velde, U. V., Crenier, L., Block, C. E. M. D., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 317 · see citing works
Self-citationTeplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273 · see citing works
Self-citationQuattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 261 · see citing works
Ogle, G. D., Wang, F., Haynes, A., Gregory, G. A., King, T. W., Deng, K., Dabelea, D., James, S., Jenkins, A. J., Li, X., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112277 · Cited by 230 · see citing works
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 222 · see citing works
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194 · see citing works
Haller, M. J., Schatz, D., Skyler, J. S., Krischer, J. P., Bundy, B. N., Miller, J. L., Atkinson, M. A., Becker, D. J., Baidal, D. A., DiMeglio, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0494 · Cited by 183 · see citing works
Self-citationHaller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Rosenthal, S. M., Shuster, J. J., Zou, B., Brusko, T. M., Hulme, M. A., Wasserfall, C. H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78492 · Cited by 167 · see citing works
Gitelman, S. E., Gottlieb, P. A., Rigby, M. R., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M. E., Moore, W. V., Pinckney, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70065-2 · Cited by 143 · see citing works
Todd, J. A., Evangelou, M., Cutler, A. J., Pękalski, M. Ł., Walker, N. M., Stevens, H. E., Porter, L., Smyth, D. J., Rainbow, D. B., Ferreira, R. C., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002139 · Cited by 138 · see citing works
Self-citationHaller, M. J., Long, S. A., Blanchfield, L., Schatz, D., Skyler, J. S., Krischer, J. P., Bundy, B. N., Geyer, S. M., WARNOCK, M. V., Miller, J. L., et al. (2019) · Diabetes · doi:10.2337/db19-0057 · Cited by 134 · see citing works
Self-citationRabbit Antithymocyte Globulin (Thymoglobulin®)
Gaber, A. O., Monaco, A. P., Russell, J. A., Lebranchu, Y., & Mohty, M. (2010) · Drugs · doi:10.2165/11315940-000000000-00000 · Cited by 86 · see citing works
Leete, P., Mallone, R., Richardson, S. J., Sosenko, J. M., REDONDO, M. J., & Evans‐Molina, C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1083-4 · Cited by 80 · see citing works
Self-citationSamuelsson, U., Lindblad, B., Carlsson, A., Forsander, G., Ivarsson, S. A., Kockum, I. S., Lernmark, Å., Marcus, C., Ludvigsson, J., & Better Diabetes Diagnosis (BDD) study group (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2365 · Cited by 50 · see citing works
Rabbit antithymocyte globulin–induced serum sickness disease and human kidney graft survival
Couvrat-Desvergnes, G., Salama, A., Berre, L. L., Evanno, G., Viklický, O., Hrubá, P., Veselý, P., Guérif, P., Dejoie, T., Rousse, J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82267 · Cited by 49 · see citing works
Seelig, E., Howlett, J., Porter, L., Truman, L. A., Heywood, J. J. N., Kennet, J., Arbon, E. L., Katerina, A., Walker, N. M., Atkar, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99306 · Cited by 44 · see citing works
Self-citationLachin, J. M., McGee, P. L., Greenbaum, C. J., Palmer, J. P., Pescovitz, M. D., Gottlieb, P. A., Skyler, J. S., & Type 1 Diabetes Trial Network (2011) · PLoS ONE · doi:10.1371/journal.pone.0026471 · Cited by 44 · see citing works
Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes
Jacobsen, L. M., Diggins, K. E., Blanchfield, L., McNichols, J., Perry, D. J., Brant, J. O., Dong, X., Bacher, R. L., Gersuk, V. H., Schatz, D. A., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.161812 · Cited by 39 · see citing works
Marcovecchio, M. L., Hendriks, E., Delfin, C., Battelino, T., Danne, T., Evans, M. L., Johannesen, J., Kaur, S., Knip, M., Overbergh, L., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06124-5 · Cited by 35 · see citing works
Self-citationAnderson, R. L., DiMeglio, L. A., Mander, A., Dayan, C. M., Linsley, P. S., Herold, K. C., Marinac, M., & Ahmed, S. T. (2022) · Diabetes Care · doi:10.2337/dc22-0308 · Cited by 23 · see citing works
Self-citationA quantitative measure of treatment response in recent‐onset type 1 diabetes
Bundy, B. N., Krischer, J. P., & for the Type 1 Diabetes TrialNet Study Group (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.143 · Cited by 22 · see citing works
Wilhelm-Benartzi, C. S., Miller, S. E., Bruggraber, S. F. A., Picton, D., Wilson, M., Gatley, K., Chhabra, A., Marcovecchio, M. L., Hendriks, E., Morobé, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053669 · Cited by 21 · see citing works
Self-citationShifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan, A. J., Gorelik, S., & Nally, L. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1477101 · Cited by 13 · see citing works
Time for changes in type 1 diabetes intervention trial designs
Atkinson, M. A., Haller, M. J., Schatz, D., Battaglia, M., & Mathieu, C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00262-0 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42 · see citing works
Self-citationToward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab
Mathieu, C., Sims, E. K., Chatenoud, L., James, E. A., Atkinson, M. A., & Herold, K. C. (2025) · Diabetes Care · doi:10.2337/dci25-0066 · Cited by 21 · see citing works
Self-citationContinuous glucose monitoring as a tool in early-stage type 1 diabetes
Carr, A. L. J., Sutton, H., Agesen, R. M., Bonifacio, E., Bosi, E., Gillard, P., Swaby, R., Vercauteren, J., & Besser, R. E. J. (2026) · Diabetologia · doi:10.1007/s00125-026-06707-4 · Cited by 8 · see citing works
Self-citationWagner, R. J., Füchtenbusch, M., Hummel, M., Miszon, M., Pfützner, A., Tan, S., & Wiesner, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113047 · Cited by 7 · see citing works
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Ballwieser, D. A., Blüher, M., Bugianesi, E., Cebrián, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 5 · see citing works
Self-citationDikranian, C., Hadara, O., & Lysy, P. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758848 · Cited by 3 · see citing works
ATG as disease-modifying therapy for new-onset type 1 diabetes
Speake, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01773-8 · Cited by 1 · see citing works
Chujo, D., Kawamura, T., Kikuchi, T., Imagawa, A., Koshiba, R., Maeda, Y., Hirota, Y., Ishii, A., Suzuki, J., Miura, J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113350 · Cited by 1 · see citing works
EASD 2025 Interview: Chantal Mathieu
Mathieu, C. (2025) · EMJ Diabetes · doi:10.33590/emjdiabet/kqfu7715
Self-citationFrom disease heterogeneity to precision therapy in type 1 diabetes mellitus
Nigi, L., Pagano, R., Sarti, F., Sebastiani, G., & Dotta, F. (2026) · Endocrine · doi:10.1007/s12020-026-04637-0
Self-citationWeber, D., Modeste, J., Peeling, S., Foster, T. P., Bruggeman, B. S., Jacobsen, L. M., Schatz, D., & Haller, M. J. (2026) · Diabetes Care · doi:10.2337/dc26-0223
Wang, Y., Zhou, Y., Zhu, M., Wang, X., Shi, X., Li, X., Huang, G., Li, L., Xie, Z., & Zhou, Z. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70829
Degroote, L., Chrzanowski, J., Lemaître, P., Wouters, A., Bourgeois, S., Mulders, A. V., Pierreux, J., Coenen, S., Willems, L., Leuckx, G., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06750-1
Self-citationWouters, A., Mathieu, C., & Gysemans, C. A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104120
Self-citationDiabetes mellitus Typ 1 – neue Aspekte in Therapie & Technologie 2026
Schmidt, A.-S., & Ebert, T. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01487-2
Immuntherapie und Zelltherapie bei Diabetes mellitus Typ 1
Schill, S., Schwenker, L., Reinmüller, F., Achenbach, P., & Ziegler, A. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02167-5
Self-citationAnti Thymocyte Globulin- Development
Banerjee, S., Manguesh, R., & Murzello, K. (2026) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-026-02576-4
- Authors
- Mathieu, C., Wych, J., Hendriks, A. E. J., Van Ryckeghem, L., Tree, T., Chmura, P., Möller, C., Casteels, K., Danne, T., Reschke, F., Šmigoc Schweiger, D., Battelino, T., Johannesen, J., Rami-Merhar, B., Pieber, T., De Block, C., Evans, M., Hilbrands, R., Bosi, E., Willemsen, R. H., Basu, S., Pulkkinen, M.-A., Knip, M., Cnop, M., Nitsche, A., Schulte, A. M., Niemöller, E., Peakman, M., Wilhelm-Benartzi, C., Gillespie, D., Overbergh, L., Mander, A. P., Marcovecchio, M. L., Mathieu, C., Overbergh, L., Evans, M., Hendriks, A. E. J., Marcovecchio, M. L., Peakman, M., Tree, T., Morgan, N. G., Todd, J. A., Wicker, L., Mander, A. P., Dayan, C. M., Wych, J., Gillespie, D., Pieber, T., Eizirik, D. L., Cnop, M., Brunak, S., Pociot, F., Johannesen, J., Mallone, R., Knip, M., Otonkoski, T., Veijola, R., Lahesmaa, R., Ziegler, A. G., Solimena, M., Bonifacio, E., Holl, R., Dotta, F., Chiarelli, F., Marchetti, P., Bosi, E., Cianfarani, S., de Beaufort, C., Dahl-Jørgensen, K., Jarosz-Chobot, P., Battelino, T., Gotthardt, M., Roep, B. O., Lundgren, M., Costecalde, G., von Herrath, M., Napolitano-Rosen, A., Niemöller, E., Keil, S., Dutta, S., Latres, E., Agiostratidou, G., & Koralova, A.
- Affiliations
- University of Copenhagen (DK)
- Universitair Ziekenhuis Leuven (BE)
- Kinderkrankenhaus auf der Bult (DE)
- Medical University of Vienna (AT)
- Vrije Universiteit Brussel (BE)
- Barts Health NHS Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
- University of Helsinki (FI)
- Sanofi (Germany) (DE)
- Cardiff University (GB)
- KU Leuven (BE)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-09
- Volume
- 406
- Issue
- 10510
- Pages
- 1375-1388
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4414400011
- Cited by
- 17
- References
- 30
- Citations by year
- 2026: 12 · 2025: 5
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- green
- orca.cardiff.ac.uk
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, other-oa)
- dCOBISS.SI Digital Repository (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Cambridge
- Universitaire Ziekenhuizen Leuven, KU Leuven
- European Federation of Pharmaceutical Industries and Associations
- Horizon 2020 Framework Programme
- JDRF
- IMI
- Innovative Medicines Initiative (115797)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antithymocyte globulin, type 1 diabetes, recent-onset type 1 diabetes, minimum effective dose, C-peptide, beta-cell function, mixed meal tolerance test, children and adolescents, disease-modifying therapy, immunomodulatory therapy
- MeSH terms
- Adolescent, Adult, Antilymphocyte Serum, Child, Child, Preschool, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
